Innovative Treatment Solutions Venclose specializes in next-generation RF therapy for chronic venous insufficiency, addressing a widespread condition affecting approximately 10% of adults, creating a sizable market for advanced minimally invasive treatments.

Strategic Partnerships The company has established collaborations with Viant since 2019, indicating an active approach to jointly developing innovative vein treatment technologies which could translate into partnership or procurement opportunities.

Recent Acquisition Venclose was acquired by Becton, Dickinson and Company in November 2021, suggesting increased resources and potential for expanded sales channels within healthcare and medical device markets.

Strong Funding Momentum With $27 million raised in Series C funding led by Ally Bridge Group, Venclose demonstrates investor confidence and the capacity to scale operations and penetration into medical institutions.

Growing Healthcare Market Operating in the medical equipment manufacturing industry with a focus on minimally invasive vascular treatments, Venclose presents opportunities to engage with hospitals, clinics, and vascular specialists seeking innovative solutions for CVI management.